Karen Andersen, biotechnology strategist for Morningstar Research Services, discusses what GLP-1 drugs’ demand means for the biopharma industry’s five-year outlook. And whether the weight-loss drugs pose a threat to snack food stocks.

Why GLP-1 Drugs Are in Demand

Competition Between Novo Nordisk and Eli Lilly

How Expanding the Conditions GLP-1 Drugs Treats Could Influence Insurance Coverage

Are Weight Loss Drugs a Threat to Snack Food Stocks?

Big Pharma’s Looming Patent Cliff

How Medicare Negotiations Impact the Pharmaceutical Industry

What is a Biologic Drug?

Upcoming Innovations in the Pharmaceutical Industry

Which BioPharma Drugs Do We Expect to Contract?

Big Pharma’s Five-Year Outlook

Biopharmaceutical Stock Picks

Read about topics from this episode.

2024 Biopharmaceutical Industry Landscape

Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?

Investment Opportunities in the Biopharma Industry

Obesity Drug Market: The Next Wave of GLP-1 Competition

What to watch from Morningstar.

Is the Fed’s Plan to Avoid a Recession Working?

Don't Overlook These Crucial Parts of Your Retirement Plan

Boating Season Is Over, but Don't Overlook These Recreational Vehicle Stocks

5 Ways to Improve America’s Retirement Savings

Read what our team is writing:

Karen Andersen

Ivanna Hampton

Follow us on social media.

Facebook: https://www.facebook.com/MorningstarInc/

X: https://x.com/MorningstarInc

Instagram: https://www.instagram.com/morningstar...

LinkedIn: https://www.linkedin.com/company/5161/

How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks

Investing Insights

How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks